

## Drugs and Pharmaceuticals Industry Highlights

### Contents

Chapter	Page	Chapter	Page
<b>Feature</b>	<b>1</b>	– NPPA asks to roll back “unjustified” price rise	
– Indian pharma industry performance 2006-2007		– States want control on drug prices	
<b>News &amp; Views</b>		– Apex drug body wants ban on 1105 brands	
<b>Indian Industry News</b>	<b>15</b>	<b>Global News</b>	<b>26</b>
– India seeks clarification from EC regarding counterfeit drugs		– GE’s \$8.1 billion deal for Abbott unit collapses	
– Drug price may rise as China cuts sops		– Counterfeit drugs on rise: OECD	
– Sikkim set to become new pharma hub		– US senate panel passes biosimillars bill	
– Pharma sector gains from rupee appreciation		– Asian nations to share bird flu samples	
– Natco buys US drug store		<b>Healthcare News</b>	<b>28</b>
– Flamingo Pharma enters UP market		– 2.5 million people in India living with HIV: NACO	
– Zydus Cadila acquires Brazilian firm Nikkho		– Rise in P3 polio cases: A cause for concern	
– Drug retailers plan a corporate entity		– India ahead in world diabetes population	
– Domestic pharma faces US firms allegations		– Govt signs \$250 m AIDS control loan pact with world bank	
– Dishman to buy Solvay Pharma vitamins unit		– New strategy adopted on diseases of poverty	
– SRL Ranbaxy set to test US samples		– WHO’s new plan to contain drug resistant TB	
– Ankur Drugs enters into marketing pact with German, Swiss firms		– Diabetes diagnostics market to touch \$15.4 bn by 2010	
– Shasun facility gets US FDA nod		<b>Product News</b>	<b>33</b>
– USV’s Daman facility gets US FDA approval		– Ranbaxy gets FDA nod for hypertension drug	
– Teva to buy domestic unit for Rs 400 cr		– Wockhardt gets US FDA nod for Fosphenytoin	
<b>Regulatory News</b>	<b>21</b>	– Natco Pharma gets US FDA nod	
– Bulk drugs price fixation		– Roche acquires novel arthritis drug from	
– Ceiling price fixation			

Japanese firm	
– Aurobindo gets MCC nod for Amoxycillin	
– Orchid gets USFDA nod for Cefepime	
– Glenmark gets US FDA nod for Terbinafine, Topiramate	
– United Biotech signs in-licensing deal	
– Elder Pharma to sell Enzymotec drug in India	
– Lupin gets UK authority nod to sell cardiac drug	
– Cipla enters deal with US firm	
– Thailand to buy generic Plavix drug from India	
– Dr Reddy's launches new diabetes drugs	
– Heritage to market granules generics in USA	
<b>R&amp;D News</b>	<b>37</b>
– Indian firms entering clinical contract research	
– Pharma industry – academia collaboration to accelerate R&D	
– TCG Life, Forest Lab in drug discovery pact	
– Shasun Pharma enters technology deal with H Lundbeck	
– Phase 0 trials could cut timelines	
– Aptuit and Laurus to form drug development company in India	
<b>Biotechnology</b>	<b>41</b>
– Avesthagen set to raise \$100 mn in three years	
– DRL developing 8 more biotech drugs	
– Price pressure effects Biocon statin growth	
– Interleukin to conduct genetic risk tests in Japan, China	
– Biotech generics may get to tap US market	
– Japanese researchers develop rice based oral vaccine	
– Novartis gets EMEA green light for biogeneric	
<b>Natural Products</b>	<b>45</b>
– Cherries rich in anti-oxidants may combat “Free Radicals”	
– Nicholas Piramal develops drug leads from Antarctic	
– US FDA ruling on dietary supplements may effect ayurvedic formulations export	
– Phytomedics raises \$9 million for late-stage rheumatoid	
– Hong Kong institute taking traditional Chinese medicine into the clinic	
– Pumpkin diet may be helpful to diabetic	
<b>Patents</b>	<b>49</b>
– Recent Indian patents in the field of drugs and pharmaceuticals	
– Patent board reserves judgement on Novartis plea	
– Lupin settles US patent row with Abbott, Astellas	
– Ranbaxy loses Lipitor patent case in Ireland	
– US firm drags Cadila to court on patent	
– US congress members want Thailand removed from "Priority Watch List"	

***Views expressed in the journal are those of the authors and the Editorial Board/Publisher takes no responsibility for the same. We are a secondary abstracting service and the veracity of information is of the source quoted and not our primary responsibility.***

***Editor***